VGA039 Clinical Trials
2 recruitingDrug
Phase 11Phase 21Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 3
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
Vega Therapeutics, Inc60 enrolled14 locationsNCT07115004
Recruiting
Phase 1Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Von Willebrand Diseases
Vega Therapeutics, Inc116 enrolled25 locationsNCT05776069